The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
intermediatearipiprazoleaugmentationakathisiaBarnes Akathisia Rating Scaletreatment-resistant depressionvenlafaxineextrapyramidal side effects
A 47-year-old female with treatment-resistant major depressive disorder has been taking venlafaxine 225 mg daily for four months with only partial response, with her PHQ-9 decreasing from 24 to 16. Six weeks ago, the PMHNP augmented with aripiprazole 2 mg daily. At today's visit, her PHQ-9 is 11 and she reports improved energy, better concentration, and less persistent sadness. However, she describes new-onset restlessness, an inability to sit still during meetings at work, and a compulsive need to pace in the evenings. She denies anxiety or worsening mood. The PMHNP is evaluating the augmentation outcome. Which of the following best represents the appropriate evaluation?
Explanation
Evaluating antidepressant augmentation requires simultaneous assessment of therapeutic benefit and emergent side effects. Aripiprazole-induced akathisia can occur at low augmentation doses and should be identified, quantified with standardized rating scales, and managed through a balanced approach that considers dose adjustment, adjunctive treatments, or alternative strategies while preserving the documented antidepressant benefit.
Key Takeaway
Akathisia is a common side effect of aripiprazole augmentation that should be evaluated with standardized rating scales, and management should balance preserving the antidepressant benefit against the side effect burden through dose adjustment or adjunctive treatment rather than automatic discontinuation.